D.E. Shaw & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

D.E. Shaw & Co’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,000	Closed	-$1.75M	–	4059
2020 Q4	$1.75M	Hold	20,000	–	–	﹤0.01%	2641
2020 Q3	$1.52M	Sell	20,000 -400	-2%	-$40.5K	﹤0.01%	2575
2020 Q2	$2.52M	Buy	20,400 +400	+2%	+$39.8K	﹤0.01%	2219
2020 Q1	$1.69M	Hold	20,000	–	–	﹤0.01%	2315
2019 Q4	$1.69M	Hold	20,000	–	–	﹤0.01%	2611
2019 Q3	$1.35M	Hold	20,000	–	–	﹤0.01%	2652
2019 Q2	$1.71M	Buy	+20,000	New	+$1.71M	﹤0.01%	2338
2019 Q1	–	Sell	-10,000	Closed	-$852K	–	3598
2018 Q4	$852K	Hold	10,000	–	–	﹤0.01%	2770
2018 Q3	$970K	Hold	10,000	–	–	﹤0.01%	2719
2018 Q2	$942K	Hold	10,000	–	–	﹤0.01%	2734
2018 Q1	$811K	Sell	10,000 -38,000	-79%	-$3.26M	﹤0.01%	2627
2017 Q4	$4.28M	Hold	48,000	–	–	0.01%	1601
2017 Q3	$4.47M	Hold	48,000	–	–	0.01%	1458
2017 Q2	$4.36M	Hold	48,000	–	–	0.01%	1450
2017 Q1	$4.21M	Sell	48,000 -60,000	-56%	-$5.34M	0.01%	1394
2016 Q4	$8.95M	Hold	108,000	–	–	0.02%	1008
2016 Q3	$9.99M	Buy	108,000 +18,000	+20%	+$1.69M	0.02%	889
2016 Q2	$7M	Hold	90,000	–	–	0.01%	1086
2016 Q1	$7.42M	Hold	90,000	–	–	0.01%	1024
2015 Q4	$9.43M	Buy	90,000 +10,000	+13%	+$1.04M	0.01%	996
2015 Q3	$8.43M	Buy	80,000 +20,000	+33%	+$2.67M	0.01%	1064
2015 Q2	$8.21M	Buy	60,000 +30,000	+100%	+$3.72M	0.01%	1131
2015 Q1	$3.74M	Buy	30,000 +20,000	+200%	+$2.12M	0.01%	1568
2014 Q4	$904K	Hold	10,000	–	–	﹤0.01%	2905
2014 Q3	$722K	Hold	10,000	–	–	﹤0.01%	3071
2014 Q2	$622K	Hold	10,000	–	–	﹤0.01%	3342
2014 Q1	$682K	Buy	+10,000	New	+$737K	﹤0.01%	3348

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

D.E. Shaw & Co's BMRN Position: Q2 2026 in Review

D.E. Shaw & Co reduced its BioMarin Pharmaceuticals (BMRN) stake by 67% in Q2 2026, selling an estimated $10.4M and leaving 92,214 shares worth $5.28M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

D.E. Shaw & Co first reported a position in BMRN in Q2 2013 and has held it in 52 quarters since. The position peaked at $146M in Q4 2022. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

D.E. Shaw & Co held 92,214 shares of BioMarin Pharmaceuticals worth $5.28M as of Q2 2026.
D.E. Shaw & Co sold 190,246 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $10.4M.
BioMarin Pharmaceuticals made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2356 holding.
D.E. Shaw & Co first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
D.E. Shaw & Co's BioMarin Pharmaceuticals position peaked at $146M in Q4 2022.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.